propafenone has been researched along with Electrocardiogram QT Prolonged in 9 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6)." | 1.72 | Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. ( Fish, FA; Gaedigk, A; Kannankeril, PJ; Radbill, AE; Sunthankar, SD; Van Driest, SL, 2022) |
| "Mirtazapine is a commonly prescribed antidepressant drug, which is also metabolized through and may modulate the CYP4502D6 pathway leading to altered metabolism of propafenone and possible adverse effects." | 1.40 | Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. ( Aryal, SR; Khan, MA; Rajpurohit, N; Stys, AT; Stys, TP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Sunthankar, SD | 1 |
| Kannankeril, PJ | 1 |
| Gaedigk, A | 1 |
| Radbill, AE | 1 |
| Fish, FA | 1 |
| Van Driest, SL | 1 |
| Gagloeva, DA | 1 |
| Dzaurova, KM | 1 |
| Zelberg, MA | 1 |
| Mironov, NY | 1 |
| Yuricheva, YA | 1 |
| Sokolov, SF | 1 |
| Golitsyn, SP | 1 |
| Tomcsányi, J | 1 |
| Tomcsányi, K | 1 |
| Marano, M | 1 |
| Goffredo, BM | 1 |
| Pisani, M | 1 |
| Filippelli, S | 1 |
| Cecchetti, C | 1 |
| Drago, F | 1 |
| Barbieri, MA | 1 |
| Nunziata, J | 1 |
| Genuini, L | 1 |
| Di Nardo, M | 1 |
| Rajpurohit, N | 1 |
| Aryal, SR | 1 |
| Khan, MA | 1 |
| Stys, AT | 1 |
| Stys, TP | 1 |
| Avci, A | 1 |
| Yilmaz, A | 1 |
| Celik, M | 1 |
| Demir, K | 1 |
| Keles, F | 1 |
| Darbar, D | 1 |
| Roden, DM | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
1 review available for propafenone and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Pharmacogenetics of antiarrhythmic therapy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arylamine N-Acetyltransferase; ATP Binding Cassette Tr | 2006 |
1 trial available for propafenone and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
7 other studies available for propafenone and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.
Topics: Adolescent; Adult; Alleles; Anti-Arrhythmia Agents; Child; Child, Preschool; Cytochrome P-450 CYP2D6 | 2022 |
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralon.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Long QT | 2023 |
Wide QRS alternans caused by propafenone toxicity.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Rate; Humans; Long QT | 2019 |
Pediatric extracorporeal cardiopulmonary resuscitation settled in an emergency department for a propafenone intentional intoxication.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electrocardiography; Emergency Se | 2018 |
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Atrial Fibrillation; Bradycardia; Di | 2014 |
Successful treatment of suicide attempt by megadose of propafenone and captopril.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 2013 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |